Bioregulators · Dosing reference

Cartalax dosage

What the human evidence does and does not show, how long studies ran, and the arithmetic for working with vials.

Not approved — research use onlyDMechanistic onlyNone established

Full research page Cycle-length evidence Compare Prefer Amiravo on Google

Regulatory status: Not approved — research use only
Human amounts: None established in humans
Route studied: —
Frequency: Not established
Half-life: Not established
Evidence grade: Grade D · Mechanistic only
Vial sizes on the market: 20 mg
Other forms seen: —

What Cartalax is

Cartalax is a short synthetic tripeptide of the bioregulator class, studied in experimental research on cartilage and connective tissue biology.

The published mechanistic account for this peptide is almost entirely descriptive, and rests on the proposal — advanced by the group that developed these compounds — that very short peptides enter cells and nuclei and modulate transcription by interacting directly with DNA or with histone tails ^6. In a Russian-language study in renal cell culture, AED was reported to reduce expression of the senescence-associated… How it works →

Key evidence

Ashapkin et al., Molecular Biology Reports · 2020 · Cells (human embryonic bone-marrow mesenchymal stem cells, FetMSC line, aged by passage or stationary culture)
AED was one of three peptides associated with a 3.5- to 5.6-fold increase in IGF1 expression and with increased NFκB expression in both ageing models; effects on FOXO1, TERT and TNKS2 differed between peptides and between the two ageing models. ³
Lin'kova et al., Bulletin of Experimental Biology and Medicine · 2016 · Cells (human skin fibroblasts during replicative ageing in culture)
All four peptides, AED among them, were associated with reduced MMP-9 synthesis and increased Ki-67 and CD98hc expression; AED and AEDG were additionally associated with suppression of caspase-dependent apoptosis. ⁴
Chalisova et al., Bulletin of Experimental Biology and Medicine · 2015 · Animal tissue ex vivo (organotypic kidney explants from young and old rats)
T-31 (AED) was reported to stimulate proliferation and reduce apoptosis in kidney explants, but less than the polypeptide complex, which raised Ki-67 and lowered p53 expression in explants from both age groups. ⁵

All studies on the research page

What the human evidence shows

No approved or established human dose

We searched PubMed and ClinicalTrials.gov and found no human studies that administered Cartalax. The research described on its page is from cells or animals, and animal amounts do not translate to people.

How long did human studies run?

No human study durations are recorded for Cartalax.

Cycle-length evidence for Cartalax

Cartalax draw calculator

Pick the vial strength and the water added, enter an amount, and see the concentration, the units to draw and how many draws the vial holds. Arithmetic only.

1 · Vial strength

sizes on the market

2 · Water added

3 · Amount per draw

4 · Syringe

Your mix

20 mg + 2 mL water = 10 mg/mL

10 units holds 1 mg

Draw toEnter an amount in step 3

U-100 syringe · 100 units = 1 mL

Computed from your inputs. Not a dose or a recommendation.

Compare water volumes for this vialShow

More water = lower concentration = a larger, easier-to-measure draw. Tap a row to use it.

Water	mg/mL	Draw
0.5 mL	40	—
1 mL	20	—
1.5 mL	13.33	—
2 mL	10	—
2.5 mL	8	—
3 mL	6.667	—
5 mL	4	—

Supplies and handling

Lyophilized vial
Sealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
Sterile diluent
The diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
Graduated syringes
Sized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
Alcohol prep pads
For wiping vial stoppers before each puncture.
Nitrile gloves
Clean gloves for aseptic handling.
Sharps container
Puncture-resistant container for used needles.

Step-by-step reconstitution guide Storage and transport accessories

Storage

Handling should follow the certificate of analysis and written documentation supplied with the specific lot; no stability or handling data specific to this compound were identified in the sources reviewed. Short lyophilised peptides are generally treated as hygroscopic, light-sensitive solids whose reconstituted solutions are chemically less stable than the dry material. Amiravo does not provide preparation, reconstitution or administration instructions.

Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.

Handling mistakes and troubleshooting

Added the wrong volume of diluent: The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.
Shook the vial and it foamed: Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.
The solution is cloudy or has particles: Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.
The powder cake looks melted or shrunken before reconstitution: This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.
Liquid sprayed back when the needle was removed: Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.

Regulatory status

Status: Not approved by the FDA for any use; no human drug labeling matching this name was returned by the openFDA Drug Label API ^10.
United States (FDA): There is no approved FDA application for this peptide; an openFDA Drug Label API query returned no matching human drug labeling ^10. Neither "cartalax" nor "Ala-Glu-Asp" appears in any of the three categories of FDA's list of bulk drug substances nominated for use in compounding under section 503A of the FD&C Act, as updated 14 May 2026 ^11.
Sport (WADA): Not named in the WADA 2026 Prohibited List ^12. That absence is hedged negative evidence and not a clearance. Section S0 prohibits at all times "any pharmacological substance which is not currently approved by any governmental regulatory health authority for human therapeutic use" and states that the class "covers many different substances including but not limited to" its named examples; section S2 prohibits the listed peptide hormones, growth factors and mimetics "and other substances with similar chemical structure or similar biological effect(s)" ^12.

Status varies by country and changes over time. How we describe regulatory status.

Cartalax compared with related compounds

Compound	Status	Evidence	Human amounts	Half-life
Cartalax	Not approved — research use only	D	None established	—
Chonluten	Not approved — research use only	D	None established	—
Epithalon	Not approved — research use only	C	None established	—
Cortagen	Not approved — research use only	C	None established	—
Cardiogen	Not approved — research use only	C	None established	—
P-21	Not approved — research use only	C	None established	—

Frequently asked questions

What doses of Cartalax have been studied in humans?

None that establish an amount. Cartalax is not approved anywhere and we found no human studies that administered it. Amiravo does not publish community or vendor figures.

Is there an established Cartalax cycle length?

No. We found no human studies that report treatment duration for Cartalax.

How much bacteriostatic water should be added to a Cartalax vial?

There is no compound-specific volume. The diluent volume only sets the concentration: concentration = mass in the vial ÷ volume added (for example, 10 mg in 2 mL gives 5 mg/mL). The calculator on this page shows the arithmetic for any combination.

How many units is a given amount on an insulin syringe?

On a U-100 syringe, 100 units = 1 mL. Units for an amount = amount ÷ (concentration per unit). The calculator converts any amount you enter at the concentration you choose; a unit is a volume mark, not an amount of compound.

Is Cartalax FDA-approved?

Not approved — research use only. Not approved by the FDA for any use; no human drug labeling matching this name was returned by the openFDA Drug Label API ^10.

References

alanyl-glutamyl-aspartic acid [Supplementary Concept] — entry terms include Ala-Glu-Asp, cartalax and T-31 peptide Medical Subject Headings, U.S. National Library of Medicine. 2026
Cartalax (CID 87815447) — compound record, C12H19N3O8, 333.29 g/mol, CAS 85806-95-7 PubChem, U.S. National Library of Medicine. 2026
Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides Molecular Biology Reports. 2020
Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro Bulletin of Experimental Biology and Medicine. 2016
Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals Bulletin of Experimental Biology and Medicine. 2015
Tripeptides slow down aging process in renal cell culture (in Russian) Advances in Gerontology (Uspekhi Gerontologii). 2014
Peptidergic regulation of thymocyte differentiation, proliferation, and apoptosis during aging of the thymus Bulletin of Experimental Biology and Medicine. 2011
Effect of short peptides on neuronal differentiation of stem cells International Journal of Immunopathology and Pharmacology. 2019
ClinicalTrials.gov registry query for "cartalax" (the single returned record is an unrelated enteral-nutrition study retrieved by fuzzy matching) ClinicalTrials.gov (U.S. National Library of Medicine). 2026
openFDA Drug Label API query for "cartalax" (no approved human drug labeling returned) U.S. Food and Drug Administration / openFDA. 2026
Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) U.S. Food and Drug Administration. 2026
World Anti-Doping Code International Standard — Prohibited List 2026 (effective 1 January 2026) World Anti-Doping Agency. 2026
PubMed query for "cartalax" (6 records, all retrieved through the MeSH mapping of the name to the tripeptide Ala-Glu-Asp) PubMed / NCBI Entrez (U.S. National Library of Medicine). 2026

Last reviewed October 23, 2026 by the Amiravo editorial team. Editorial policy · Report an error